Efficient inhibition of ovarian cancer by recombinant CXC chemokine ligand 10 delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels

Oncology Reports

Volumn 28, Issue 2, 2012, Pages 668-676

  Yang, Fan ^a,b   Gou, Malin ^a,b   Deng, Hongxin ^a,b   Yi, Tao ^a,b   Zhong, Qian ^a,b   Wei, Yuquan ^a,b   Zhao, Xia ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Apoptosis; Gene therapy; HPEI; IP 10; Ovarian cancer

Indexed keywords

ALGINIC ACID; CD31 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GREEN FLUORESCENT PROTEIN; KI 67 ANTIGEN; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOMATOSIS; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHEMOKINE CXCL10; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENETIC THERAPY; HEPARIN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PLASMIDS; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863487796     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1853     Document Type: Article

References (43)

1. Jermal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. DiSaia PJ and Creasman WT: Epithelial ovarian cancer. In: Clinical Gynecologic Oncology. 5th edition, 1997.
4. Farber J and Mig M: IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 61: 246-247, 1997.
5. Loetscher M, Loetscher P, Brass N, Meese E and Moser B: Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur J Immunol 28: 3696-3705, 1998. (Pubitemid 28510780)
6. Neville LF, Mathiak G and Bagasra O: The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the CXC chemokine superfamily. Cytokine Growth Factor Rev 8: 207-219, 1997. (Pubitemid 28077928)
7. Douglas A, Arenberg A, Steven LK and Unkelfl PJ: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360, 2004.
8. Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK and Romero IA: Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol 199: 35-45, 2008.
9. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER, McDonald HA, Gibson GA, Watkins SC and Muthuswamy R: Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells - significant roles of CXCL10. Cancer Res 69: 1587-1595, 2009.
10. Strieter RM, Polverini PJ, Kunkel SL, et al: The functional role of the ELR motif in CXC chemokine mediated angiogenesis. J Biol Chem 270: 348-357, 1995.
11. Boussif O, Lezoualc'h F, Zanta MA, et al: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92: 7297-7301, 1995.
12. Lungwitz U, Breunig M, Blunk T and Gopferich A: Polyethylenimine-based non-viral gene delivery systems. Eur J Pharm Biopharm 60: 247-266, 2005. (Pubitemid 40804565)
13. Neu M, Fischer D and Kissel T: Recent advances in rational gene transfer vector design based on poly (ethyleneimine) and its derivatives. J Gene Med 7: 992-1009, 2005. (Pubitemid 41195062)
14. Kunath K, Von HA, Fischer D, et al: Low-molecular weight polyethyleneimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethyleneimine. J Control Release 89: 113-125, 2003. (Pubitemid 36412116)
15. Gou M, Men K, Zhang J, et al: Efficient inhibition of C-26 colon carcinoma by VSVMP gene delivered by biodegradable cationic nanogel derived from polyethyleneimine. ACS Nano 4: 5573-5584, 2010.
16. Chuan X, Ma LG, Tao Y, et al: Efficient inhibition of ovarian cancer by truncation mutant of FILIP1L gene delivered by novel biodegradable cationic heparin-polyethyleneimine nanogels. Hum Gene Ther 22: 1413-1422, 2011.
17. Baudin B, Bruneel A, Bosselut N and Vaubourdolle M: A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protoc 2: 481-485, 2007. (Pubitemid 47040010)
18. Wen Y, Wang C, Ma T, Li Z, Zhou L, Mu B, Leng F, Shi H, Li Y and Wei Y: Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 101: 2325-2332, 2010.
19. Qiaoyun S, Andrew T, Guyen N, Angell Y, et al: A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass non-specific uptake in vivo. Gene Ther 17: 1085-1097, 2010.
20. Jen-Tsan C, Howard YC, Nancy NW, Dustin SC, Nina D and Patrick OB: Genome wide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 11: 6343-6346, 2003.
21. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 63: 1311-1316, 2003. (Pubitemid 36348710)
22. Xu GX, Zhong Y, Munir S, Yang BB, Tsang BK and Peng C: Nodal induces apoptosis and inhibits proliferation in human epithelial ovarian cancer cells via activin receptor-like kinase 7. J Clin Endocrinol Metab 89: 5523-5534, 2004. (Pubitemid 39518436)
23. Lin XJ, Chen XC, Wei YQ, et al: Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 104: 540-546, 2007.
24. Folkman J: Angiogenesis: an organizing principle for drug discovery. Nat Rev Drug Discov 6: 273-286, 2007.
25. Hillen F and Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26: 489-502, 2007. (Pubitemid 350115123)
26. Lin XJ, Chen XC, Wang L, et al: Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. J Exp Clin Cancer Res 26: 467-474, 2007. (Pubitemid 351157862)
27. Sun C, Yi T, Song X, Li S, Qi X, Chen X, Lin H, He X, Li Z, Wei Y and Zhao X: Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol Rep 26: 193-200, 2011.
28. Hoffmann J, Schirner M, Menrad A and Schneider MR: A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res 57: 3847-3851, 1997. (Pubitemid 27381234)
29. Fan Y, Li Z, Hong XD, et al: Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. Oncology 75: 137-144, 2008.
30. Takayama K, Ueno H, Nakanishi Y, et al: Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 60: 2169-2177, 2000. (Pubitemid 30225180)
31. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP and Ramakrishnan S: Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 60: 2190-2196, 2000. (Pubitemid 30225182)
32. Herbst RS, Mullani NA, Davis DW, et al: Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20: 3804-3814, 2002.
33. Schmidt NO, Ziu M, Carrabba G, et al: Antiangiogenic therapy by local intracerebral microinfusion improves treatment effi- ciency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 10: 1255-1262, 2004. (Pubitemid 38365215)
34. Folkman J: Angiogenesis and apoptosis. Semin Cancer Biol 13: 159-167, 2003.
35. Alberts DS, Clouser MC, Hess LM, Springer V, Heidel B and Howell SB: Selection of drugs for intraperitoneal chemotherapy for ovarian cancer. Intraperitoneal Ther Ovarian Cancer 1: 77-88, 2010.
36. Malek A, Bakhidze E, Noske A, et al: HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer 123: 348-356, 2008. (Pubitemid 351842019)
37. Nguyen TMB, Subramanian IV, Xiao X, et al: Adenoassociated virus-mediated delivery of kringle 5 of human plasminogen inhibits orthotopic growth of ovarian cancer. Gene Ther 17: 606-615, 2010.
38. Young LS and Mautner V: The promise and potential hazards of adenovirus gene therapy. Gut 48: 733-736, 2001. (Pubitemid 32378601)
39. Zhdanov RI, Podobed OV and Vlassov V: Cationic lipid-DNA complexes - lipoplexes - for gene transfer and therapy. Bioelectrochemistry 58: 53-64, 2002. (Pubitemid 36160467)
40. Gao Y, Xu Z, Chen S, et al: Arginine-chitosan/DNA selfassemble nanoparticles for gene delivery: in vitro characteristics and transfection efficiency. Int J Pharm 359: 241-246, 2008.
41. Montier T, Benvegnu T, Jaffre's PA, et al: Progress in cationic lipid-mediated gene transfection: a series of bioinspired lipids as an example. Curr Gene Ther 8: 296-312, 2008.
42. Morille M, Passirani C, Vonarbourg A, et al: Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 29: 3477-3496, 2008.
43. Suzuki R, Namai E, Oda Y, et al: Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release 142: 245-250, 2010.